SBIR/STTR Research Award

Optically Sensorized, Actuated Needles for Oncological Applications

Award identifier 02ce289bb50e675ddd741d5fbb6c8dd53c1c620d4b0bf54935405c0621d7f4e1Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$2,052,624

Program and phase

SBIR · Phase II – Direct to Phase II

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
INTELLIGENT FIBER OPTIC SYSTEMS CORP
Proposal award date
2019-07-01
Contract end date
2021-06-30
UEI
HCXHVBD9HKN9
Solicitation number
PA18-574
Topic code
102

Research abstract

Optically Sensorized, Actuated Needles for Oncological Applications Intelligent Fiber Optic Systems Corporation (IFOS) 2363 Calle del Mundo, Santa Clara, CA 95054-1008 www.ifos.com PROJECT SUMMARY/ABSTRACT (MAXIMUM 30 LINES) In this Direct-to-Phase-II SBIR application, IFOS and Texas Aandamp;M University propose to develop and validate an actively steered, tendon-actuated, small-caliber needle for precise imaging-assisted percutaneous procedures with focus on deep tissue biopsies. Interviews with clinicians have confirmed that steering capability would greatly improve clinical methods for biopsy and drug delivery. With current methods, precise needle placement is not always possible in procedures targeting deep tissue, where routes of entry are restricted due to anatomical obstructions and the need to avoid vital organs. Furthermore, as the needle is inserted, forces from the surrounding tissue cause the needle to deflect off the planned path. Such deviations result in multiple reinsertions, adding to patient discomfort and procedure time, and compromising the effectiveness of minimally invasive procedures. The proposed active steering can compensate for deflection encountered during insertion, which becomes increasingly significant as the path to the target lengthens. The active steering concept is based on linear servo motors that actuate needle tip flexion through connected tendon fibers. The design feature of a hollow NiTi needle allows for applications like drug delivery and laser ablation when another needle is inserted within the host needle core. This design also incorporates a removable core with attached fiber Bragg gratings to sense obstructing internal body parts, reducing the need for assistive MR imaging during the procedure. Imaging technologies are still options if the operator wants to view these obstructions during the procedure, since the needle itself is MRI compatible. In prior work, bending rates of over 2 degrees per second have been repeatably achieved in phantoms that mimic the properties of human prostate tissue, and, we have implemented a thinner needle design, an intuitive console design concept, and a closed-loop control system that enables real-time needle curvature and in situ tissue reaction force measurements. The initial effort is designed to demonstrate still greater deflection efficiency using various needle insertion strategies and finalize the design of the clinically deployable needle and the associated controlling console with input from experts and potential consumers. This work will lead to further development activities, including thinner needle designs, an enhanced console design for implementation, and a closed-loop control system that enables real-time needle curvature and in situ tissue reaction force measurements. The IFOS team will also investigate steering protocols that would take advantage of axial rotation and other known passive control strategies, thereby adding bending degrees-of-freedom and dexterity to the needle system. These studies will culminate in a series of in vivo experiments, targeting liver/kidney biopsy and drug delivery procedures. Optimizing the needle for these specific clinical applications will drive the innovative IFOS product towards commercialization.Project Narrative The proposed Phase II project will reduce the need for multiple biopsy needle reinsertions by commercializing an innovative steerable needle with optical sensorization. To achieve this, we will test our needle with an animal study to finalize the design and verify ease of use. This approach will ensure that the needle meets consumer needs and is ready for manufacturing so that we may provide a more accurate interventional device for oncologic applications.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

172 SBIR/STTR records share this UEI (1994–2025). Reported award amounts total $61,008,158. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Defense, National Aeronautics and Space Administration, Department of Energy, Department of Health and Human Services, National Science Foundation, Department of Agriculture

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.